Porous carbon particles for use in the treatment or prevention of liver disease
AssigneesUCL Business PLC, University of Brighton
InventorsCarol Angela Howell, Sergey Victorovich Mikhalovsky, Susan Rachel Sandeman, Rajiv Jalan, Jane MacNaughtan
Life of this patent
Estimating the term…
Abstract
The invention provides porous carbon particles for use in the treatment or prevention of liver disease, wherein at least 20% of the total pore volume is made up of pores having a mean diameter of from 2 to 200 nm and/or wherein the particles comprise micropores of diameter 2 nm or less and small macropores of diameter 50 nm to 500 nm, but substantially no mesopores of diameter greater than 2 nm and less than 50 nm, and substantially no large macropores of diameter greater than 500 nm.
Claims28
A method of treating liver disease or preventing progression of liver disease to cirrhosis and its complications, comprising:
- administering an effective amount of porous carbon particles wherein 20% to 90% of a total pore volume of the porous carbon particles is made up of pores having a mean diameter of 2 nm or less and 75% or more of the remainder of the total pore volume is made up of pores having a mean diameter of from 30 nm to 500 nm, wherein the porous carbon particles are administered orally or rectally.
A method of modulating the gut-liver axis, comprising administering an effective amount of porous carbon particles, wherein 20% to 90% of a total pore volume of the porous carbon particles is made up of pores having a mean diameter of 2 nm or less and 75% or more of the remainder of the total pore volume is made up of pores having a mean diameter of from 30 nm to 500 nm, wherein the porous carbon particles are administered orally or rectally.
A method of treatment of a disease or condition selected from coronary artery disease, inflammatory bowel disease, irritable bowel syndrome, pouchitis, hypertension, stroke, obesity or complications of obesity, comprising administering an effective amount of porous carbon particles, wherein 20% to 90% of a total pore volume of the porous carbon particles is made up of pores having a mean diameter of 2 nm or less and 75% or more of the remainder of the total pore volume is made up of pores having a mean diameter of from 30 nm to 500 nm, wherein the particles are administered orally or rectally.
Porous carbon particles, wherein 20% to 90% of a total pore volume is made up of pores having a mean diameter of 2 nm or less and 75% or more of the remainder of the total pore volume is made up of pores having a mean diameter of from 30 nm to 500 nm, wherein the particles are coated in order to control their release and adsorption properties.
A method of treating liver disease or preventing progression of liver disease to cirrhosis and its complications, the method comprising:
- administering an effective amount of porous carbon particles, wherein 20% to 90% of a total pore volume of the porous carbon particles is made up of pores having a mean diameter of 2 nm or less and 75% or more of the remainder of the total pore volume is made up of pores having a mean diameter of from 30 nm to 500 nm, wherein the particles are coated in order to control their release and adsorption properties.
A method of modulating the gut-liver axis, comprising administering an effective amount of porous carbon particles, wherein 20% to 90% of a total pore volume of the porous carbon particles is made up of pores having a mean diameter of 2 nm or less and 75% or more of the remainder of the total pore volume is made up of pores having a mean diameter of from 30 nm to 500 nm, wherein the particles are coated in order to control their release and adsorption properties.
A method of treatment of a disease or condition selected from coronary artery disease, inflammatory bowel disease, irritable bowel syndrome, pouchitis, hypertension, stroke, obesity or complications of obesity, the method comprising:
- administering an effective amount of porous carbon particles, wherein 20% to 90% of a total pore volume of the porous carbon particles is made up of pores having a mean diameter of 2 nm or less and 75% or more of the remainder of the total pore volume is made up of pores having a mean diameter of from 30 nm to 500 nm, wherein the particles are coated in order to control their release and adsorption properties.
Dependencies are inferred from the claim text.